Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — improved long-term survival overall compared with chemotherapy alone, according to a landmark study published June 2 in the New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology (ASCO), the world’s leading professional organization for physicians and oncology professionals caring for patients with cancer.
